136 related articles for article (PubMed ID: 15039600)
1. Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer.
Gallicchio L; Lord G; Tkaczuk K; Danton M; Lewis LM; Lim CK; Flaws JA
Breast Cancer Res Treat; 2004 May; 85(1):89-97. PubMed ID: 15039600
[TBL] [Abstract][Full Text] [Related]
2. Aging may be associated with concentrations of tamoxifen and its metabolites in breast cancer patients.
Sheth HR; Lord G; Tkaczuk K; Danton M; Lewis LM; Langenberg P; Lim CK; Flaws JA
J Womens Health (Larchmt); 2003 Oct; 12(8):799-808. PubMed ID: 14588130
[TBL] [Abstract][Full Text] [Related]
3. Medication use, tamoxifen (TAM), and TAM metabolite concentrations in women with breast cancer.
Gallicchio L; Tkaczuk K; Lord G; Danton M; Lewis LM; Lim CK; Flaws JA
Cancer Lett; 2004 Jul; 211(1):57-67. PubMed ID: 15194217
[TBL] [Abstract][Full Text] [Related]
4. Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours.
MacCallum J; Cummings J; Dixon JM; Miller WR
Br J Cancer; 2000 May; 82(10):1629-35. PubMed ID: 10817496
[TBL] [Abstract][Full Text] [Related]
5. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
Garreau JR; Delamelena T; Walts D; Karamlou K; Johnson N
Am J Surg; 2006 Oct; 192(4):496-8. PubMed ID: 16978958
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients.
Tucker AN; Tkaczuk KA; Lewis LM; Tomic D; Lim CK; Flaws JA
Cancer Lett; 2005 Jan; 217(1):61-72. PubMed ID: 15596297
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial.
Hale MJ; Howell A; Dowsett M; Cuzick J; Sestak I
Breast; 2020 Dec; 54():216-221. PubMed ID: 33160147
[TBL] [Abstract][Full Text] [Related]
8. Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites.
Jager NG; Koornstra RH; Vincent AD; van Schaik RH; Huitema AD; Korse TM; Schellens JH; Linn SC; Beijnen JH
BMC Cancer; 2013 Dec; 13():612. PubMed ID: 24373320
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22.
Baxter SD; Teft WA; Choi YH; Winquist E; Kim RB
Breast Cancer Res Treat; 2014 Jun; 145(2):419-28. PubMed ID: 24744093
[TBL] [Abstract][Full Text] [Related]
10. Decision-making impairments in breast cancer patients treated with tamoxifen.
Chen X; Li J; Chen J; Li D; Ye R; Zhang J; Zhu C; Tian Y; Wang K
Horm Behav; 2014 Jul; 66(2):449-56. PubMed ID: 25036869
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.
Kimmick GG; Lovato J; McQuellon R; Robinson E; Muss HB
Breast J; 2006; 12(2):114-22. PubMed ID: 16509835
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene is associated with less side effects than tamoxifen in women with early breast cancer: a questionnaire study from one physician's practice.
Rohatgi N; Blau R; Lower EE
J Womens Health Gend Based Med; 2002 Apr; 11(3):291-301. PubMed ID: 11988138
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen-induced hot flashes.
Loprinzi CL; Zahasky KM; Sloan JA; Novotny PJ; Quella SK
Clin Breast Cancer; 2000 Apr; 1(1):52-6. PubMed ID: 11899390
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.
Rouanet P; Linares-Cruz G; Dravet F; Poujol S; Gourgou S; Simony-Lafontaine J; Grenier J; Kramar A; Girault J; Le Nestour E; Maudelonde T
J Clin Oncol; 2005 May; 23(13):2980-7. PubMed ID: 15860853
[TBL] [Abstract][Full Text] [Related]
16. Profiles of tamoxifen-related side effects by race and smoking status in women with breast cancer.
Zhan M; Flaws JA; Gallicchio L; Tkaczuk K; Lewis LM; Royak-Schaler R
Cancer Detect Prev; 2007; 31(5):384-90. PubMed ID: 18023540
[TBL] [Abstract][Full Text] [Related]
17. Determination of tamoxifen--DNA adducts in leukocytes from breast cancer patients treated with tamoxifen.
Umemoto A; Monden Y; Lin CX; Abdul-Momen M; Ueyama Y; Komaki K; Laxmi YR; Shibutani S
Chem Res Toxicol; 2004 Dec; 17(12):1577-83. PubMed ID: 15606132
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of tamoxifen and its 4-hydroxy and N-desmethyl metabolites: activation of caspases and induction of apoptosis in rat mammary tumors and in human breast cancer cell lines.
Mandlekar S; Hebbar V; Christov K; Kong AN
Cancer Res; 2000 Dec; 60(23):6601-6. PubMed ID: 11118041
[TBL] [Abstract][Full Text] [Related]
19. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
Cuzick J; Sestak I; Cella D; Fallowfield L;
Lancet Oncol; 2008 Dec; 9(12):1143-8. PubMed ID: 18976959
[TBL] [Abstract][Full Text] [Related]
20. Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer.
Johnston SR; Haynes BP; Sacks NP; McKinna JA; Griggs LJ; Jarman M; Baum M; Smith IE; Dowsett M
Breast Cancer Res Treat; 1993 Dec; 28(3):241-50. PubMed ID: 8018953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
